Company intelligence / Profile preview

Libratum

San Diego, California, United Stateslibratumcounseling.com ↗

Ownership: Private
Development stage: Other

Overview

Libra Therapeutics is developing small molecule therapeutics aimed at restoring lysosomal function and cellular balance to halt or slow neurodegeneration. Their lead program targets TRPML1 and is expected to enter Phase 1 clinical trials in 2025. The company operates virtually, partnering with CROs for R&D activities[2][3][4].

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Axxampotential clinical development partners

Beyond the preview

Go deeper on Libratum.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Libratum.

Explore the full profile